Abstract
AMG 701 is an anti-BCMA BiTE® with characteristics suitable for once-weekly dosing in multiple myeloma (MM) patients. We here evaluated AMG 701-mediated (i) T cell-dependent cellular cytotoxicity (TDCC) of MM cells with or without MM-supporting cells from the bone marrow (BM) microenvironment, (ii) changes in T cells and (iii) TDCC in combination with immunomodulatory drugs (IMiDs). AMG 701 induced TDCC of (i) BCMA+ MM cells resistant or sensitive to current anti-MM agents including bortezomib (PIs) and IMiDs, (ii) lenalidomide (len)- and pomalidomide (pom)-resistant MM cells in the presence of osteoclasts (OCs), BM stromal cells (BMSCs), or a proliferation-inducing ligand (100 ng/ml).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
